---
title: "Castle Biosciences, Inc. (CSTL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CSTL.US.md"
symbol: "CSTL.US"
name: "Castle Biosciences, Inc."
industry: "Health Care Services"
datetime: "2026-04-16T04:02:40.523Z"
locales:
  - [en](https://longbridge.com/en/quote/CSTL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CSTL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CSTL.US.md)
---

# Castle Biosciences, Inc. (CSTL.US)

## Company Overview

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets.

| Item | Detail |
|------|--------|
| Industry | Health Care Services |
| Exchange | US Market |
| Website | [castlebiosciences.com](https://castlebiosciences.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-15T04:30:17.000Z

**Overall: C (0.48)**

**Industry**: Health Care Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 41 / 89 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3.66% |  |
| Net Profit YoY | -232.41% |  |
| P/B Ratio | 1.54 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 724549295.26 |  |
| Revenue | 344229000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -5.21% | D |
| Profit Margin | -7.02% | D |
| Gross Margin | 79.37% | A |
| Revenue YoY | 3.66% | C |
| Net Profit YoY | -232.41% | E |
| Total Assets YoY | 8.91% | B |
| Net Assets YoY | 3.30% | C |
| Cash Flow Margin | -266.36% | E |
| OCF YoY | 3.66% | C |
| Turnover | 0.62 | B |
| Gearing Ratio | 18.61% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Castle Biosciences, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "3.66%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-232.41%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.54",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "724549295.26",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "344229000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-5.21%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-7.02%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "79.37%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "3.66%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-232.41%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.91%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "3.30%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-266.36%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "3.66%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.62",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "18.61%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -30.30 | 62/89 | 33.62 | 33.04 | 31.38 |
| PB | 1.55 | 19/89 | 2.37 | 1.50 | 1.24 |
| PS (TTM) | 2.13 | 50/89 | 3.22 | 2.00 | 1.61 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cigna (CI.US) | B | B | A | D | B | B |
| 02 | BrightSpring Health Services - Unit (BTSGU.US) | C | A | A | D | A | B |
| 03 | Fresenius (FSNUY.US) | C | B | C | C | B | B |
| 04 | Labcorp (LH.US) | B | C | B | C | B | B |
| 05 | Quest Diagnostics (DGX.US) | B | B | B | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-27T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 24.62 |
| Highest Target | 52.00 |
| Lowest Target | 44.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CSTL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CSTL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CSTL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CSTL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**